Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
71.78
-0.45 (-0.62%)
At close: Apr 28, 2026, 4:00 PM EDT
72.00
+0.22 (0.31%)
After-hours: Apr 28, 2026, 5:56 PM EDT
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 22 analysts with 12-month price forecasts for Ionis Pharmaceuticals stock have an average target of 93.14, with a low estimate of 46 and a high estimate of 130. The average target predicts an increase of 29.76% from the current stock price of 71.78.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ionis Pharmaceuticals stock from 22 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 9 | 9 |
| Buy | 8 | 9 | 9 | 9 | 10 | 10 |
| Hold | 4 | 4 | 4 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 22 | 22 | 22 | 23 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $110 → $108 | Strong Buy | Maintains | $110 → $108 | +50.46% | Apr 23, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $110 | Strong Buy | Initiates | $110 | +53.25% | Apr 21, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $95 → $130 | Buy | Maintains | $95 → $130 | +81.11% | Apr 21, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $100 → $111 | Strong Buy | Maintains | $100 → $111 | +54.64% | Apr 9, 2026 |
| Barclays | Barclays | Buy Maintains $95 → $106 | Buy | Maintains | $95 → $106 | +47.67% | Mar 26, 2026 |
Financial Forecast
Revenue This Year
843.89M
from 943.71M
Decreased by -10.58%
Revenue Next Year
1.50B
from 843.89M
Increased by 77.99%
EPS This Year
-4.19
from -2.38
EPS Next Year
-1.36
from -4.19
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 955.6M | 2.2B | ||||||
| Avg | 843.9M | 1.5B | ||||||
| Low | 749.1M | 1.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.3% | 155.8% | ||||||
| Avg | -10.6% | 78.0% | ||||||
| Low | -20.6% | 40.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.23 | 1.22 | ||||||
| Avg | -4.19 | -1.36 | ||||||
| Low | -4.60 | -3.88 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.